PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis

Cancer Letters

Volumn 284, Issue 2, 2009, Pages 157-164

  Zeng, Fu Yue ^a   Cui, Jimmy ^a   Liu, Lingling ^a   Chen, Taosheng ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Alveolar rhabdomyosarcoma; Apoptosis; Camptothecin; Differential cytotoxicity; PAX3 FKHR

Indexed keywords

CAMPTOTHECIN; HYBRID PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG IDENTIFICATION; DRUG SENSITIZATION; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RHABDOMYOSARCOMA; SARCOMA CELL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CELL DIVISION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; RHABDOMYOSARCOMA, ALVEOLAR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 69549119999     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.016     Document Type: Article

References (32)

1. Raney R.B., Anderson J.R., Barr F.G., Donaldson S.S., Pappo A.S., Qualman S.J., Wiener E.S., Maurer H.M., and Crist W.M. l. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V. J. Pediatr. Hematol. Oncol. 23 (2001) 215-220
2. Linardic C.M. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett. 270 (2008) 10-18
3. Barr F.G. Fusions involving paired box and fork head family transcription factors in the pediatric cancer alveolar rhabdomyosarcoma. Curr. Top. Microbiol. Immunol. 220 (1997) 113-129
4. Barr F.G. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomyosarcoma. Cancer Res. 59 (1999) 1711-1715
5. Sorensen P.H., Lynch J.C., Qualman S.J., Tirabosco R., Lim J.F., Maurer H.M., Bridge J.A., Crist W.M., Triche T.J., and Barr F.G. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 20 (2002) 2672-2679
6. Kikuchi K., Tsuchiya K., Otabe O., Gotoh T., Tamura S., Katsumi Y., Yagyu S., Tsubai-Shimizu S., Miyachi M., Iehara T., and Hosoi H. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 365 (2008) 568-574
7. Ebauer M., Wachtel M., Niggli F.K., and Schafer B.W. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 26 (2007) 7267-7281
8. Taulli R., Scuoppo C., Bersani F., Accornero P., Forni P.E., Miretti S., Grinza A., Allegra P., Schmitt-Ney M., Crepaldi T., and Ponzetto C. Validation of Met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res. 66 (2006) 4742-4749
9. Mercado G.E., Xia S.J., Zhang C., Ahn E.H., Gustafson D.M., Laé M., Ladanyi M., and Barr F.G. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chrom. Cancer 47 (2008) 510-520
10. Tomescu O., Xia S.J., Strezlecki D., Bennicelli J.L., Ginsberg J., Pawel B., and Barr F.G. Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab. Invest. 84 (2004) 1060-1070
11. Taniguchi E., Nishijo K., McCleish A.T., Michalek J.E., Grayson M.H., Infante A.J., Abboud H.E., Legallo R.D., Qualman S.J., Rubin B.P., and Keller C. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 27 (2008) 6550-6560
12. Amstutz R., Wachtel M., Troxler H., Kleinert P., Ebauer M., Haneke T., Oehler-janne C., Fabbro D., Niggli F.K., and Schafer B.W. Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res. 68 (2008) 3767-3775
13. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6 (2006) 789-806
14. Beretta G.L., Perego P., and Zunino F. Mechanisms of cellular resistance to camptothecins. Curr. Med. Chem. 13 (2006) 3291-3305
15. Rasheed A.Z., and Rubin E.H. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22 (2003) 7296-7304
16. Pappo A.S., Lyden E., Breneman J., Wiener E., Teot L., Meza J., Crist W., and Vietti T. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J. Clin. Oncol. 19 (2001) 213-219
17. Goldwasser F., Bae I., Valenti M., Torres K., and Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55 (1995) 2116-2121
18. Desai S.D., Li T.K., Rodriguez-Bauman A., Rubin E.H., and Liu L.F. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 61 (2001) 5926-5932
19. Davis P.L., Shaiu W.L., Scott G.L., Iglehart J.D., Hsieh T.S., and Marks J.R. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res. 18 (1998) 2919-2932
20. Nakashio A., Fujita N., Rokudai S., Sato S., and Tsuruo T. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res. 60 (2000) 5303-5309
21. Lee S., Lee H.S., Baek M., Lee D.Y., Bang Y., Cho H.N., Lee Y.S., Ha J.H., Kim H.Y., and Jeong D. MAPK signaling is involved in camptothecin-induced cell death. Mol. Cells 14 (2002) 348-354
22. Xia S.J., Rajput P., Strzelecki D.M., and Barr F.G. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein. Lab Invest. 87 (2007) 318-325
23. Lin W.W., Wu J., Dong H.Q., Bouck D., Zeng F.Y., and Chen T.S. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J. Biol. Chem. 283 (2008) 30650-30657
24. Chen T., Wang L.H., and Farrar W.L. Interleukin-6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 60 (2000) 2132-2135
25. Boyd J.M., Huang L., Xie L., Moe B., Gabos S., and Li X.F. A cell-microelectronic sensing technique for profiling cytotoxicity of chemicals. Anal. Chim. Acta 615 (2008) 80-87
26. Tomicic M.T., Christmann M., and Kaina B. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res. 65 (2008) 8920-8926
27. Gibson A.A., Harwood F.G., Tillman D.M., and Houghton J.A. Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression. Clin. Cancer Res. 4 (1998) 145-152
28. Wang Z., Smith K.S., Murphy M., Piloto O., Somervaille T.C., and Cleary M.L. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455 (2008) 1205-1209
29. Davicioni E., Finckenstein F.G., Shahbazian V., Buckley J.D., Triche T.J., and Anderson M.J. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 66 (2006) 6936-6946
30. Albihn A., Mo H., Yang Y., and Henriksson M. Camptothecin-induced apoptosis is enhanced by MYC and involves PKCdelta signaling. Int. J. Cancer 121 (2007) 1821-1829
31. Roeb W., Boyer A., Covenee W.K., and Arden K.C. Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle 7 (2008) 837-841
32. Bersani F., Taulli R., Accornero P., Morotti A., Miretti S., Crepaldi T., and Ponzetto C. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur. J Cancer. 44 (2008) 876-884